Integrated Approaches for Design of Precision Cancer Immunotherapies: Selection of Class I and Class II T cell Neo-Epitopes and Removal Treg Epitopes

by Annie De Groot | Mar 1, 2019

2018 Design of Cancer Immunotherapies – Selection of Neo-Epitopes, Removal of Tregitopes

New Regression Model Predicts Antibody Immunogenicity Based on Effector and Regulatory T Cell Epitope Content

by Annie De Groot | Dec 14, 2018

EpiVax_AET18_New Regression Model Predicts Antibody Immunogenicity_5Dec18

From infectious disease to personalized cancer vaccines: Regulatory T cell epitopes determine patient outcomes and suppress neoantigen responses

by Annie De Groot | Nov 6, 2018

EpiVax_Oncology_Ancer_SITC_05Nov18_39Wx35H

Innovative Preclinical Assessment Tools for Safety and Efficacy of Protein and Peptide Therapeutics…of Peptides and P-ANDAS

by Annie De Groot | Oct 30, 2018

EpiVax_EuroTIDES_PANDA_02Nov18 To learn more about EpiVax’s PANDA Program, read our latest entries. PANDA screening Interview with Brian Roberts: Protein Therapeutics Manager PANDA Press Release

Designing a Better Assay – HLA-DR Binding Assays as a Tool for Immunogenicity Screening: Developing the Best Practices for Determining Immunogenicity

by Annie De Groot | Oct 9, 2018

EpiVax_AAPS HLA-binding poster epivax format[1]